Naklofen (Diclofenac Sodium)

Diclofenac Sodium, the active ingredient in Naklofen, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an intramuscular injection solution for intramuscular use. It is indicated for mild to moderate pain, inflammatory musculoskeletal conditions, postoperative pain, and rheumatic disorders in adult patients. GNH USA supplies Naklofen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diclofenac Sodium is employed to manage pain and inflammation in musculoskeletal and postoperative settings.

Mild to moderate pain: provides analgesia to reduce discomfort. Inflammatory musculoskeletal conditions: decreases swelling and improves joint function. Post‑operative pain: controls surgical site discomfort and facilitates recovery. Rheumatic disorders: alleviates chronic inflammation associated with rheumatoid arthritis and related diseases.

Adverse reactions may occur with intramuscular diclofenac administration.

Common Side Effects: - Injection site pain or irritation. - Nausea or dyspepsia. - Headache. - Dizziness. - Mild skin rash.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Hepatic injury or elevated liver enzymes. - Renal impairment or acute kidney injury. - Severe allergic reactions, including anaphylaxis. - Cardiovascular events such as myocardial infarction or stroke.

Prior to initiating therapy, consider the following safety measures.

Assess renal function: evaluate baseline kidney function and monitor during treatment. Monitor hepatic enzymes: check liver function tests before and during use. Avoid in active peptic ulcer disease: consider alternative analgesics. Use with caution in elderly patients: increased susceptibility to adverse events. Store at ambient temperature: keep in original container, protect from light and moisture.

Diclofenac Sodium may interact with several drug classes; awareness helps prevent complications.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Selective COX‑2 inhibitors: additive gastrointestinal toxicity. - Lithium: potential increase in serum lithium levels. - Methotrexate: reduced clearance leading to toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors: possible reduction in renal function. - Diuretics: increased risk of renal impairment. - Corticosteroids: synergistic risk of gastrointestinal ulceration.